Verge Genomics, which is developing treatments for ALS and Parkinson's, has raised series A funding from backers including WuXi AppTec.

MedWhat insists Stanford University failed to disclose a conflict of interest when it invested in rival virtual medical assistant developer Sensely.

Ascentage, spun out of Ascenta Therapeutics and backed by 3SBio, has increased its total funding to more than $240m after closing a $150m series C round.

HealthCap has backed sickle cell disease therapy developer Modus Therapeutics, joining existing shareholders such as Karolinska Development.

LabCorp returned for the first close of a round that took the genetic disease drug developer's total funding to $50m.

BlueCross BlueShield Venture Partners led care management platform Octave's series A round, which included Echo Health Ventures.

The personalised cancer therapy company has completed a $40m round that increased its funding to $76m altogether.

University of Tokyo Edge Capital joined a second close that expanded the cell therapy developer's series B round by an extra $11m.

The Tata-backed personalised cancer therapy developer has completed a $40m round that increased its funding to $76m altogether.